Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, Inc [2019] FCA 526

Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, Inc [2019] FCA 526

The application to withdraw the Ester Admission is refused because there is substantial evidence against the applicant's new position, the applicant has not undertaken a reasonably simple experiment to clarify the admission's accuracy, and withdrawal would likely jeopardise the trial date, running counter to case management principles.

Jurisdiction
Australia
Judgment Date
16 April 2019
Procedural Posture
Interlocutory Application / Application for Leave to Withdraw Admissions in Defence to Cross Claim
Outcome
Application dismissed
Legal Topics
['interlocutory Application' 'withdrawal of Admissions' 'patent Infringement' 'case Management' 'cross Claim']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Interlocutory Application / Application for Leave to Withdraw Admissions in Defence to Cross Claim

  1. 1 ["Whether leave should be granted to withdraw an admission (the 'Ester Admission') in defence to a cross-claim for patent infringement" 'Consideration of case management principles and impact on trial date']

Ratio Decidendi

The application to withdraw the Ester Admission is refused because there is substantial evidence against the applicant's new position, the applicant has not undertaken a reasonably simple experiment to clarify the admission's accuracy, and withdrawal would likely jeopardise the trial date, running counter to case management principles.

Court Disposition

Application dismissed

Orders

  • ["The applicant's interlocutory application dated 5 March 2019 be dismissed."]